___

• 1. Tadros RO, Vouyouka AG, Ting W, Teodorescu V, Kim SY, Marin ML, Faries PL. A Review of Superficial Femoral Artery Angioplasty and Stenting. J Vasc Med Surg 2015; 3(1):1-5 2. Drachman DE. Endovascular Treatment of the Superficial Femoral Artery: When Nothing Is Actually Quite Something. J Am Coll Cardiol. 2019;73(6):680-683. 3. Yokoi Y, Fukuda K, Fujihara M, Higashimori A, Kawarada O. Angiography and Endovascular Therapy for Femoropopliteal Artery Disease, Angiography and Endovascular Therapy for Peripheral Artery Disease. IntechOpen 2017:3 DOI: 10.5772/67181 4. Rose G. Bulletin of W.H.O. 1962;27:645-57. Hirsch AT, et al. J Am Coll Cardiol. 2006;47:1239–312. 5. Sato K, Iida O, Takahara M, Soga Y, Suzuki K, Tanigawa T, Ito M, Uematsu M. Effect of perioperative complications after endovascular therapy in patients with peripheral artery disease due to femoropopliteal lesions. J Vasc Surg. 2015 May;61(5):1272-7. 6. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001 May 24;344(21):1608-21. 7. Adili F, Balzer K, Betz T, Billing A, Böckler D, Brixner D, et al. A current practice of first-line treatment strategies in patients with critical limb ischemia. J Vasc Surg 2015; 62: 965–973. 8. Powell RJ. Endovascular Treatment in the Superficial Femoral Artery: Which Devices, Where? Seminars in Vascular Surgery. 2008;21(4):180-185. 9. Dake MD, Ansel GM, Jaff MR, et al. Paclitax eleluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 2011;4:495–504. 10. Rosenfield K, Jaff MR, White CJ, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med 2015;373:145–53